The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Abbvie
Ibrutinib in association with R-DHAP/ox for patients with relapsed/refractory b-cell lymphoma: Results of the escalating phase of the BIBLOS phase Ib LYSA study.
 
Christophe Marc Bonnet
Consulting or Advisory Role - Janssen-Cilag; Roche; Servier/Pfizer
 
Thierry Lamy
No Relationships to Disclose
 
Christophe Fruchart
No Relationships to Disclose
 
Steven Le Gouill
No Relationships to Disclose
 
Katharina Gunzer
No Relationships to Disclose
 
Thomas Gastinne
No Relationships to Disclose
 
Fabrice Jardin
No Relationships to Disclose
 
Lionel Karlin
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda (I)
 
Roch Houot
No Relationships to Disclose
 
Jehan Dupuis
No Relationships to Disclose
 
Herve Tilly
Honoraria - Celgene; Roche/Genentech; SERVIER
Consulting or Advisory Role - AstraZeneca; Karyopharm Therapeutics; Roche
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Roche
 
Gilles A. Salles
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Gilead Sciences; Gilead Sciences; Janssen; Novartis; Roche/Genentech; SERVIER
Consulting or Advisory Role - Acerta Pharma; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Kite, a Gilead company; Merck; Novartis; Novimmune; Pfizer; Roche/Genentech; SERVIER
Research Funding - Celgene; Gilead Sciences; Merck; Roche/Genentech; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech; Sanofi